2022
Fenofibrate Downregulates NF-κB Signaling to Inhibit Pro-inflammatory Cytokine Secretion in Human THP-1 Macrophages and During Primary Biliary Cholangitis
Gallucci GM, Alsuwayt B, Auclair AM, Boyer JL, Assis DN, Ghonem NS. Fenofibrate Downregulates NF-κB Signaling to Inhibit Pro-inflammatory Cytokine Secretion in Human THP-1 Macrophages and During Primary Biliary Cholangitis. Inflammation 2022, 45: 2570-2581. PMID: 35838934, PMCID: PMC10853883, DOI: 10.1007/s10753-022-01713-1.Peer-Reviewed Original ResearchConceptsPrimary biliary cholangitisPrimary sclerosing cholangitisAnti-inflammatory mechanismsChronic liver diseaseNF-κB signalingBiliary cholangitisLiver diseaseNF-κB p50IL-1βIL-8Peroxisome proliferator-activated receptor alphaPro-inflammatory cytokine secretionProliferator-activated receptor alphaIncomplete biochemical responseAnti-inflammatory effectsAddition of fenofibratePro-inflammatory cytokinesPPARα-dependent mannerHuman THP-1 macrophagesP65 protein expressionLabel therapeutic optionTHP-1 macrophagesTHP-1 cellsSclerosing cholangitisAdult patients
2021
Adjunct Fenofibrate Up‐regulates Bile Acid Glucuronidation and Improves Treatment Response For Patients With Cholestasis
Gallucci GM, Trottier J, Hemme C, Assis DN, Boyer JL, Barbier O, Ghonem NS. Adjunct Fenofibrate Up‐regulates Bile Acid Glucuronidation and Improves Treatment Response For Patients With Cholestasis. Hepatology Communications 2021, 5: 2035-2051. PMID: 34558841, PMCID: PMC8631103, DOI: 10.1002/hep4.1787.Peer-Reviewed Original ResearchConceptsSerum bile acidsSerum alkaline phosphataseBile acidsTreatment responseIncomplete responseTotal serum bile acidsElevated serum alkaline phosphatasePeroxisome proliferator-activated receptor alphaProliferator-activated receptor alphaAlkaline phosphatasePrimary sclerosing cholangitisPrimary biliary cholangitisStandard of careSerum ALP levelsBile acid glucuronidationCytotoxic bile acidsPrimary human hepatocytesBA detoxificationFenofibrate therapySclerosing cholangitisAdult patientsBiliary cholangitisLiver failureCombination therapyImproved outcomesOutcome of COVID‐19 in Patients With Autoimmune Hepatitis: An International Multicenter Study
Efe C, Dhanasekaran R, Lammert C, Ebik B, la Tijera F, Aloman C, Calışkan A, Peralta M, Gerussi A, Massoumi H, Catana AM, Torgutalp M, Purnak T, Rigamonti C, Aldana A, Khakoo N, Kacmaz H, Nazal L, Frager S, Demir N, Irak K, Ellik ZM, Balaban Y, Atay K, Eren F, Cristoferi L, Batıbay E, Urzua Á, Snijders R, Kıyıcı M, Akyıldız M, Ekin N, Carr RM, Harputluoğlu M, Hatemi I, Mendizabal M, Silva M, Idilman R, Silveira M, Drenth JPH, Assis DN, Björnsson E, Boyer JL, Invernizzi P, Levy C, Schiano TD, Ridruejo E, Wahlin S. Outcome of COVID‐19 in Patients With Autoimmune Hepatitis: An International Multicenter Study. Hepatology 2021, 73: 2099-2109. PMID: 33713486, PMCID: PMC8250536, DOI: 10.1002/hep.31797.Peer-Reviewed Original ResearchConceptsSevere COVID-19Chronic liver diseaseAutoimmune hepatitisLiver injuryMulticenter studyCOVID-19Causes of CLDPropensity score-matched cohortSevere COVID-19 outcomesContinuation of immunosuppressionMaintenance of immunosuppressionOutcomes of patientsIntensive care admissionUse of antiviralsInternational multicenter studyCOVID-19 outcomesCOVID-19 diagnosisContinued immunosuppressionCare admissionCause mortalityIndependent predictorsMedian ageLiver diseaseMechanical ventilationRetrospective study
2020
Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol
Ghonem NS, Auclair AM, Hemme CL, Gallucci GM, de la Rosa Rodriguez R, Boyer JL, Assis DN. Fenofibrate Improves Liver Function and Reduces the Toxicity of the Bile Acid Pool in Patients With Primary Biliary Cholangitis and Primary Sclerosing Cholangitis Who Are Partial Responders to Ursodiol. Clinical Pharmacology & Therapeutics 2020, 108: 1213-1223. PMID: 32480421, PMCID: PMC7886378, DOI: 10.1002/cpt.1930.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBile Acids and SaltsBiomarkersCholangitis, SclerosingCytokinesDrug Therapy, CombinationFemaleFenofibrateHumansInflammation MediatorsLiverLiver Cirrhosis, BiliaryLiver Function TestsMaleMiddle AgedPPAR alphaPrincipal Component AnalysisRetrospective StudiesTreatment OutcomeUrsodeoxycholic AcidYoung AdultConceptsPrimary sclerosing cholangitisPrimary biliary cholangitisBile acid metabolismSclerosing cholangitisBiliary cholangitisBile acidsAcid metabolismPeroxisome proliferator-activated receptor alphaProliferator-activated receptor alphaRetrospective observational studyBeneficial clinical effectsCholestatic liver diseasePro-inflammatory cytokinesBile acid metabolitesHealthy control subjectsBile acid poolSerum alkaline phosphataseAminotransferase abnormalitiesUrsodiol therapyFenofibrate therapyPartial respondersBile acid precursorsClinical effectsFenofibrate treatmentLiver disease
2019
Bile‐Derived Organoids From Patients With Primary Sclerosing Cholangitis Recapitulate Their Inflammatory Immune Profile
Soroka CJ, Assis DN, Alrabadi LS, Roberts S, Cusack L, Jaffe AB, Boyer JL. Bile‐Derived Organoids From Patients With Primary Sclerosing Cholangitis Recapitulate Their Inflammatory Immune Profile. Hepatology 2019, 70: 871-882. PMID: 30561836, DOI: 10.1002/hep.30470.Peer-Reviewed Original ResearchMeSH KeywordsAdultBileCholangiopancreatography, Endoscopic RetrogradeCholangitis, SclerosingCytokinesFemaleFluorescent Antibody TechniqueGene Expression RegulationGenome-Wide Association StudyHumansImaging, Three-DimensionalMaleMiddle AgedOrganoidsRegistriesSensitivity and SpecificitySignal TransductionStem CellsTissue Culture TechniquesConceptsPSC patientsTumor necrosis factor alphaEpithelial cellular adhesion moleculePrimary sclerosing cholangitisChemokine ligand 20End-stage diseaseEndoscopic retrograde cholangiopancreatographyHuman leukocyte antigenT cell chemoattractantNecrosis factor alphaCellular adhesion moleculesGamma-glutamyl transferaseImmune-related genesSclerosing cholangitisClinical courseImmune profileInterleukin-17AProinflammatory mediatorsRetrograde cholangiopancreatographyLeukocyte antigenAnion exchanger 2Factor alphaInflammatory stimuliEffective treatmentBiliary-like cells
2017
Primary Sclerosing Cholangitis Is Not Rare Among Blacks in a Multicenter North American Consortium
Goldberg DS, Levy C, Yimam K, Gordon SC, Forman L, Verna E, Yu L, Rahimi R, Schwarz K, Eksteen B, Pratt D, Boyer JL, Assis D, Bowlus C. Primary Sclerosing Cholangitis Is Not Rare Among Blacks in a Multicenter North American Consortium. Clinical Gastroenterology And Hepatology 2017, 16: 591-593. PMID: 29102704, PMCID: PMC5860952, DOI: 10.1016/j.cgh.2017.10.028.Peer-Reviewed Original ResearchCombination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis
Assis DN, Abdelghany O, Cai SY, Gossard AA, Eaton JE, Keach JC, Deng Y, Setchell KD, Ciarleglio M, Lindor KD, Boyer JL. Combination Therapy of All-Trans Retinoic Acid With Ursodeoxycholic Acid in Patients With Primary Sclerosing Cholangitis. Journal Of Clinical Gastroenterology 2017, 51: e11-e16. PMID: 27428727, PMCID: PMC5218875, DOI: 10.1097/mcg.0000000000000591.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAlanine TransaminaseAlkaline PhosphataseBile Acids and SaltsCholagogues and CholereticsCholangitis, SclerosingCholestenonesDrug Therapy, CombinationFemaleHumansLiverLiver Function TestsMaleMiddle AgedPilot ProjectsTreatment OutcomeTretinoinUrsodeoxycholic AcidYoung AdultConceptsPrimary sclerosing cholangitisUrsodeoxycholic acidAlanine aminotransferaseUDCA monotherapyPrimary endpointSclerosing cholangitisMedian serum alanine aminotransferasePilot studyWeeks of therapyMarkers of inflammationSerum alanine aminotransferaseRetinoic acidAlkaline phosphataseAll-Trans Retinoic AcidSerum ALP levelsHuman pilot studyCombination of ATRAAddition of ATRABile acid synthesisTrans retinoic acidExploratory pilot studyALT levelsAccepted therapyWeek 12C4 levels
2015
Canalicular membrane MRP2/ABCC2 internalization is determined by Ezrin Thr567 phosphorylation in human obstructive cholestasis
Chai J, Cai SY, Liu X, Lian W, Chen S, Zhang L, Feng X, Cheng Y, He X, He Y, Chen L, Wang R, Wang H, Boyer JL, Chen W. Canalicular membrane MRP2/ABCC2 internalization is determined by Ezrin Thr567 phosphorylation in human obstructive cholestasis. Journal Of Hepatology 2015, 63: 1440-1448. PMID: 26212029, PMCID: PMC4686151, DOI: 10.1016/j.jhep.2015.07.016.Peer-Reviewed Original ResearchMeSH KeywordsAdultBile CanaliculiCase-Control StudiesCholestasisCytoskeletal ProteinsFemaleGallstonesGene Knockdown TechniquesHep G2 CellsHumansLiverMaleMembrane ProteinsMiddle AgedModels, BiologicalMultidrug Resistance-Associated Protein 2Multidrug Resistance-Associated ProteinsPhosphorylationProtein Kinase CReceptors, Autocrine Motility FactorRNA, MessengerThreonineConceptsObstructive cholestasisCholestatic liverMRP2 expressionMrp2 internalizationHepG2 cellsHuman obstructive cholestasisMRP2 protein expressionMembrane expressionHepatic MRP2 expressionNon-cholestatic controlsExpression of PKCαTotal protein levelsBile ductCholestatic patientsCholestasisBile acidsPatientsAbstractTextHuman liverProtein expressionProtein levelsLiverMRP2JaundiceAIMS
2013
The role of macrophage migration inhibitory factor in autoimmune liver disease
Assis DN, Leng L, Du X, Zhang CK, Grieb G, Merk M, Garcia AB, McCrann C, Chapiro J, Meinhardt A, Mizue Y, Nikolic‐Paterson D, Bernhagen J, Kaplan MM, Zhao H, Boyer JL, Bucala R. The role of macrophage migration inhibitory factor in autoimmune liver disease. Hepatology 2013, 59: 580-591. PMID: 23913513, PMCID: PMC3877200, DOI: 10.1002/hep.26664.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntigens, Differentiation, B-LymphocyteBiomarkersBiopsyCase-Control StudiesCohort StudiesFemaleGene FrequencyHepatitis, AutoimmuneHistocompatibility Antigens Class IIHumansIntramolecular OxidoreductasesLiverLiver Cirrhosis, BiliaryMacrophage Migration-Inhibitory FactorsMaleMicrosatellite RepeatsMiddle AgedPhenotypePolymorphism, Single NucleotideConceptsMacrophage migration inhibitory factorPrimary biliary cirrhosisAutoimmune hepatitisMigration inhibitory factorMIF receptorHealthy controlsInhibitory factorAutoimmune liver diseaseMIF promoter polymorphismsHepatic stellate cellsEnzyme-linked immunosorbentCATT7 alleleImmunopathogenic basisMIF expressionMIF locusBiliary cirrhosisLiver diseaseInflammatory phenotypeReceptor profileStellate cellsPromoter polymorphismPatientsSerum samplesCD74Single nucleotide polymorphisms
1997
Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei
Setchell K, Rodrigues C, Clerici C, Solinas A, Morelli A, Gartung C, Boyer J. Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei. Gastroenterology 1997, 112: 226-235. PMID: 8978363, DOI: 10.1016/s0016-5085(97)70239-7.Peer-Reviewed Original ResearchConceptsBile acid concentrationsBile acid administrationBile duct ligationBile acid poolLiver tissueBile acidsAcid administrationRat liver tissueDuct ligationTotal bile acid concentrationTissue concentrationsBile acid compositionSham-operated ratsLiver tissue levelsMajor bile acidsHydrophobic bile acidsHepatocyte nucleiAcid poolHuman liver tissueExperimental cholestasisAbstractTextTissue levelsRat hepatic nucleiAcid concentrationAdministration
1995
A randomized, double‐blind, placebo‐controlled trial of ursodeoxycholic acid in primary biliary cirrhosis
Combes B, Carithers R, Maddrey W, Lin D, McDonald M, Wheeler D, Eigenbrodt E, Muñoz S, Rubin R, Garcia‐Tsao G, Bonner G, West A, Boyer J, Luketic V, Shiffman M, Mills A, Peters M, White H, Zetterman R, Rossi S, Hofmann A, Markin R. A randomized, double‐blind, placebo‐controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995, 22: 759-766. PMID: 7657280, DOI: 10.1002/hep.1840220311.Peer-Reviewed Original ResearchConceptsPrimary biliary cirrhosisSerum bilirubinBiliary cirrhosisStratum 1Advanced primary biliary cirrhosisPlacebo-controlled trialBile acid poolLiver histologyPrognostic factorsTreatment failureSingle doseUrsodeoxycholic acidSevere symptomsPatientsUrsodiolLaboratory testsPlaceboHistologyBilirubinCirrhosisBiochemical testsGood responseStratum 3Acid poolLess effectHyperammonemic coma due to parenteral nutrition in a woman with heterozygous ornithine transcarbamylase deficiency
Felig D, Brusilow S, Boyer J. Hyperammonemic coma due to parenteral nutrition in a woman with heterozygous ornithine transcarbamylase deficiency. Gastroenterology 1995, 109: 282-284. PMID: 7797025, DOI: 10.1016/0016-5085(95)90295-3.Peer-Reviewed Original ResearchConceptsOrnithine transcarbamylase deficiencyParenteral nutritionNormal liver function test resultsLiver function test resultsLow plasma citrullineTotal parenteral nutritionFunction test resultsTolerance test resultsPartial enzyme deficiencyPartial ornithine transcarbamylase deficiencyUlcerative colitisParenteral alimentationHyperammonemic encephalopathyCase reportPlasma citrullineHyperammonemic comaPlasma glutamineAdult womenUnique caseSimilar episodesElevated levelsEnzyme deficiencySymptomatic expressionHemizygous malesWomen
1987
Improved survival with primary sclerosing cholangitis A review of clinicopathologic features and comparison of symptomatic and asymptomatic patients
Helzberg J, Petersen J, Boyer J. Improved survival with primary sclerosing cholangitis A review of clinicopathologic features and comparison of symptomatic and asymptomatic patients. Gastroenterology 1987, 92: 1869-1875. PMID: 3569762, DOI: 10.1016/0016-5085(87)90618-4.Peer-Reviewed Original ResearchConceptsPrimary sclerosing cholangitisIntrahepatic ductal systemSclerosing cholangitisClinicopathologic featuresDuctal systemKaplan-Meier life-table analysisLong-term prognosisGroup of patientsDifferent clinical characteristicsSerum bilirubin levelsOnset of diseaseUniversity Medical CenterLife-table analysisBiliary sclerosisAsymptomatic patientsPortal hypertensionClinical characteristicsLiver centersBilirubin levelsClinical featuresLiver diseaseMild diseasePoor prognosisMean ageFemale ratio
1985
Asymptomatic primary biliary cirrhosis A progress report on long-term follow-up and natural history
Beswick D, Klatskin G, Boyer J. Asymptomatic primary biliary cirrhosis A progress report on long-term follow-up and natural history. Gastroenterology 1985, 89: 267-271. PMID: 4007417, DOI: 10.1016/0016-5085(85)90325-7.Peer-Reviewed Original ResearchConceptsAsymptomatic primary biliary cirrhosisPrimary biliary cirrhosisBiliary cirrhosisAsymptomatic stateGeneral populationInitial liver biopsySubgroup of patientsLife table survival analysisDevelopment of symptomsMedian followPortal granulomasOverall survivalProgressive diseaseLiver biopsyLiver diseaseMedian periodAutoimmune disordersExtended followHistologic featuresBenign outcomeCirrhosisPatientsSurvival analysisNatural historySymptoms
1981
Prognostic indicators of hepatic injury following jejunoileal bypass performed for refractory obesity: A prospective study
Haines N, Baker A, Boyer J, Glagov S, Schneir H, Jaspan J, Ferguson D. Prognostic indicators of hepatic injury following jejunoileal bypass performed for refractory obesity: A prospective study. Hepatology 1981, 1: 161-167. PMID: 7286895, DOI: 10.1002/hep.1840010212.Peer-Reviewed Original ResearchConceptsJejunoileal bypassInactive cirrhosisWeight lossHepatic injuryLiver biopsyPericentral fibrosisClinical liver failureOral nutritional supplementationAlcoholic liver diseaseSerum aspartate aminotransferaseGreater weight lossRapid weight lossCryptogenic cirrhosisRefractory obesityAsymptomatic patientsOlder patientsLiver failureLiver injuryLiver diseaseParenteral alimentationFatty infiltrationHistologic evidenceProspective studyPrognostic indicatorClinical evaluation
1980
Aminopyrine n-Demethylation: A Prognostic test of liver function in patients with alcoholic liver disease
Schneider J, Baker A, Haines N, Hatfield G, Boyer J. Aminopyrine n-Demethylation: A Prognostic test of liver function in patients with alcoholic liver disease. Gastroenterology 1980, 79: 1145-1150. PMID: 6777231, DOI: 10.1016/0016-5085(80)90906-3.Peer-Reviewed Original ResearchConceptsAminopyrine breath testAlcoholic liver diseaseBreath testLiver diseaseAlcoholic hepatitisClinical improvementHistologic severityLiver functionConventional liver function testsLiver function testsGroup of patientsShort-term survivalClinical featuresFunction testsHistologic confirmationClinical statusProthrombin timePatientsPrognostic testDiseaseHepatitisSeveritySurvivalSGPTSGOTBone disease in primary biliary cirrhosis: Reversal of osteomalacia with oral 25-hydroxyvitamin D
Reed J, Meredith S, Nemchausky B, Rosenberg I, Boyer J. Bone disease in primary biliary cirrhosis: Reversal of osteomalacia with oral 25-hydroxyvitamin D. Gastroenterology 1980, 78: 512-517. PMID: 7351289, DOI: 10.1016/0016-5085(80)90865-3.Peer-Reviewed Original ResearchConceptsPrimary biliary cirrhosisBiliary cirrhosisBone biopsyBone diseaseIliac crest bone biopsiesMineralized bone massVitamin D deficiencyRelative osteoid volumeCrest bone biopsiesTrabecular bone volumeLow serum concentrationsD deficiencyD therapySerum concentrationsOsteoid volumeBone massTreatment periodOsteoid surfaceBone volumeOsteomalaciaHistomorphometric analysisCirrhosisPatientsBone mineralizationBiopsy
1979
Liver Failure With Steatonecrosis After Jejunoileal Bypass: Recovery With Parenteral Nutrition and Reanastomosis
Baker A, Elson C, Jaspan J, Boyer J. Liver Failure With Steatonecrosis After Jejunoileal Bypass: Recovery With Parenteral Nutrition and Reanastomosis. JAMA Internal Medicine 1979, 139: 289-292. PMID: 106783, DOI: 10.1001/archinte.1979.03630400021012.Peer-Reviewed Original ResearchConceptsJejunoileal bypassLiver failureNutritional repletionBiopsy specimensSerial liver biopsy specimensMinimal portal fibrosisLiver biopsy specimensPostoperative biopsy specimensIntestinal reanastomosisRefractory obesityHistologic improvementMild cirrhosisParenteral nutritionPortal fibrosisProlonged courseReanastomosisBypassCirrhosisPatientsPrevious reportsRepletionNutritionFailureHypoprothrombinemiaSteatonecrosisNonalcoholic liver disease Overlooked causes of liver injury in patients with heavy alcohol consumption
Levin D, Baker A, Riddell R, Rochman H, Boyer J. Nonalcoholic liver disease Overlooked causes of liver injury in patients with heavy alcohol consumption. The American Journal Of Medicine 1979, 66: 429-434. PMID: 433949, DOI: 10.1016/0002-9343(79)91064-7.Peer-Reviewed Original ResearchConceptsAlcoholic liver diseaseNonalcoholic liver diseaseLiver diseaseLiver biopsyHeavy alcohol consumptionAlcohol consumptionHepatitis B surface antigenSerum glutamic oxaloacetic transaminaseB surface antigenGlutamic oxaloacetic transaminaseAcute hepatitisChronic hepatitisTransaminase ratioConsecutive patientsLiver injuryAppropriate therapyClinical featuresLiver disordersOverlooked causeAlcoholic subjectsPatientsSurface antigenOxaloacetic transaminaseBiopsyDisease
1978
Validation of 13CO2 breath analysis as a measurement of demethylation of stable isotope labeled aminopyrine in man
Schneider J, Schoeller D, Nemchausky B, Boyer J, Klein P. Validation of 13CO2 breath analysis as a measurement of demethylation of stable isotope labeled aminopyrine in man. Clinica Chimica Acta 1978, 84: 153-162. PMID: 639299, DOI: 10.1016/0009-8981(78)90489-8.Peer-Reviewed Original ResearchConceptsLiver diseaseHepatic microsomal drug metabolismMicrosomal drug metabolismSimultaneous oral administrationDrug-drug interactionsNon-invasive assessmentN-demethylation activityOral doseCumulative excretionOral administrationEffects of diseaseExcretion of labelAdult subjectsDrug metabolismDiseaseExpired breathCumulative appearanceHuman subjectsPatientsReproducible increaseAminopyrineRadiation riskExcretionSubjectsHours